retatrutide study news today Phase III demonstrates 30% weight loss Retatrutide for weight loss: Study

Nausea becomes more common at 2mg, affecting roughly 15-20% of users

It is often referred to as the silent killer because it typically presents no noticeable symptoms, yet it increases the risk of heart disease, stroke, and other serious conditions

These trials will provide definitive evidence regarding long-term efficacy, safety, and cardiovascular outcomes specific to retatrutide

Energy expenditure contributions come primarily from glucagon receptor activation

Any circadian advantage from morning injection would be modest at best and has not been demonstrated in controlled studies

Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ (2019) Mineralocorticoid antagonism and diabetic kidney disease